Beijing Biostar Pharmaceuticals Co., Ltd. (HKG: 2563)

Market Cap	5.57B
Revenue (ttm)	73.41M
Net Income (ttm)	-208.93M
Shares Out	364.59M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	244,600
Open	21.10
Previous Close	21.00
Day's Range	16.30 - 21.10
52-Week Range	16.30 - 39.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Beijing Biostar Pharmaceuticals

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of metastasis breast cancer, advanced non-small cell lung cancer, solid tumor, and Glioblastoma. It also engages in the development of Utidelone oral capsule that is in phase II/III clinical trials; Utidelone nano formulation; and Utidelo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Country: China
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2563

Financial Performance

In 2023, Beijing Biostar Pharmaceuticals's revenue was 66.64 million, an increase of 103.03% compared to the previous year's 32.82 million. Losses were -189.64 million, 18.2% more than in 2022.

Financial numbers in CNY